1. Home
  2. AHCO vs ANAB Comparison

AHCO vs ANAB Comparison

Compare AHCO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AdaptHealth Corp.

AHCO

AdaptHealth Corp.

HOLD

Current Price

$10.16

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$56.07

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHCO
ANAB
Founded
2012
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Nursing Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
AHCO
ANAB
Price
$10.16
$56.07
Analyst Decision
Strong Buy
Buy
Analyst Count
4
12
Target Price
$13.50
$71.67
AVG Volume (30 Days)
1.1M
465.0K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
91.02
EPS
N/A
N/A
Revenue
$3,244,857,000.00
$234,603,000.00
Revenue This Year
$9.00
N/A
Revenue Next Year
$6.93
$52.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
157.01
52 Week Low
$8.33
$17.11
52 Week High
$13.43
$73.30

Technical Indicators

Market Signals
Indicator
AHCO
ANAB
Relative Strength Index (RSI) 43.82 48.33
Support Level $9.87 $53.46
Resistance Level $10.21 $57.70
Average True Range (ATR) 0.31 2.50
MACD 0.07 0.20
Stochastic Oscillator 67.98 60.25

Price Performance

Historical Comparison
AHCO
ANAB

About AHCO AdaptHealth Corp.

AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: